Listonstreetpulse.com announces that researchers at the National Institutes of Health (NIH), National Cancer Institute (NCI) and Northeastern University used Arrayit Corporation’s (OTC: ARYC) Microarray Platform to discover biomarkers important in the treatment of prostate cancer.
The research conducted by Dr. Christopher T. Campbell, Dr. James L. Gulley, Dr. Oyindasola Oyelaran, Dr. James W. Hodge, Dr. Jeffrey Schlom, and Dr. Jeffrey C. Gildersleeve has been published in the 2013 edition of Clinical Cancer Research. The paper is entitled “Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF” and can be read in its entirety at the following link: http://basicmed.med.ncku.edu.tw/public/project/1298-1363133864-1.pdf. Scientists at NCI used ARYC’s patented and proprietary SMP2 and SMP3 microarray printing technology to manufacture glycan microarrays containing miniaturized collections of carbohydrates that selectively react with IgG and IgM antibodies in serum derived from prostate cancer patients.
The important retrospective study included 141 subjects from Phase II trials of PROSTVAC-VF, a poxvirus-based cancer vaccine. PROSTVAC-VF has been in Phase III clinical trials for advanced prostate cancer. The NCI microarrays manufactured using ARYC technology consistently stratified the patients into groups with different survival rates, suggesting that the test can be used to empower personalized medicine, which bases treatment options on the characteristics of individual patients. The researchers emphasize that “By targeting treatment to likely responders, a predictive method can be significantly improve clinical efficacy while simultaneously reducing health care costs.”
Arrayit’s technology offers the highest testing specificity and sensitivity on the market, which is increasingly allowing doctors to stratify their patients into responders, non-responders and adverse responders, a capability that is empowering safer and more efficacious treatment with life-saving medicines.
To read more about ARYC and subscribe to a monthly update, CEO interview etc, please click here – http://www.listonstreetpulse.com/tag/ARYC/
About Arrayit Corporation
Arrayit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company’s innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. Arrayit’s products are used by every major research center in the world.
About Liston Street Pulse
Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Over the years, Liston Street Pulse’s original and unbiased analysis has helped the investor community immensely.
###
